The CCl4 Model for Liver Disease Research

Carbon tetrachloride, commonly abbreviated CCl4, is the most widely used toxic agent for inducing liver fibrosis in laboratory mice and rats, and it has held that position for decades.¹ The model works by poisoning the liver in a controlled, repeatable way that mirrors key stages of chronic human liver disease: initial cell death, inflammation, scar tissue buildup, and, if the toxin is withdrawn, partial or full reversal. That combination of tunability and biological relevance is why researchers studying everything from anti-fibrotic drugs to liver cancer still reach for CCl4 more than half a century after it first entered the laboratory toolkit.²

How CCl4 Damages the Liver

CCl4 is not directly toxic to liver cells. The damage starts only after the liver’s own detoxification machinery converts the compound into something far more dangerous. Enzymes in the cytochrome P450 family, particularly CYP2E1, strip a chlorine atom off the molecule and produce a trichloromethyl radical (CCl3). That radical can then react with oxygen to form an even more reactive species, the trichloromethyl peroxyl radical (CCl3OO).³ These radicals attack proteins, fats, and DNA inside liver cells. One of the most studied consequences is lipid peroxidation, a chain reaction in which the fats in cell membranes are broken down. That destabilizes the cell, disrupts the liver’s ability to process and export fats, and leads to fatty degeneration and outright cell death.²

The fact that the liver itself activates CCl4 is a feature of the model, not a quirk. It means the damage is concentrated exactly where researchers want it: in the liver, and specifically in the zone around the central vein where CYP2E1 is most abundant. That zonal pattern resembles the damage seen in several human liver diseases, including alcohol-related liver injury.

The Two-Phase Inflammatory Response

Liver cell death from CCl4 unfolds in two overlapping waves. The first is the direct chemical assault described above. The second, beginning roughly eight hours later, involves the immune system. Kupffer cells, the resident immune cells of the liver, become activated by the oxidative debris left behind by the dying hepatocytes. Once switched on, they release inflammatory signaling molecules including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).⁴

Research using mice genetically engineered to lack functional Kupffer cells has shown that this second wave genuinely worsens the damage. In normal mice, blood levels of TNF-α and IL-6 spiked 24 hours after CCl4 exposure. In Kupffer-cell-deficient mice, those spikes did not occur, and overall liver damage was reduced.⁴ This two-phase design makes the model useful for studying not just initial injury but also the inflammatory amplification loop that drives chronic liver disease in humans.

From Injury to Fibrosis

A single dose of CCl4 causes acute injury that the liver can repair. Repeated dosing over weeks, however, triggers the scarring process known as fibrosis. The central players in this transition are hepatic stellate cells (HSCs). In a healthy liver, stellate cells sit quietly and store vitamin A. When they sense repeated rounds of damage and inflammation, they activate, transforming into collagen-producing machines that lay down scar tissue.

Activated stellate cells ramp up production of alpha-smooth muscle actin (α-SMA) and type I collagen, two hallmark proteins of fibrotic liver tissue.⁵ Researchers can track the progression of fibrosis by measuring hydroxyproline (a component of collagen) in liver tissue, or by staining tissue samples to visualize the accumulating collagen fibers. CCl4 protocols of eight weeks or longer reliably produce fibrosis that is histologically graded the same way human liver biopsies are graded, from mild (F1) to cirrhotic (F4).

A single-cell atlas of CCl4-induced fibrosis recently mapped how each cell type in the liver responds differently at each stage. Using almost 50,000 individual cell nuclei from mouse livers at progressive time points, researchers found that the process is not a simple linear ramp-up. Hepatocyte proliferation gradually becomes exhausted, stellate cells lose their ability to clear themselves through programmed cell death, and the liver’s blood vessel lining switches from an anti-angiogenic to a pro-angiogenic program as fibrosis advances.⁶ These stage-specific shifts would be difficult to detect without single-cell resolution, and the CCl4 model’s predictable timeline makes it well suited for that kind of time-course experiment.

Fibrosis Can Reverse, and the Model Shows How

One of the CCl4 model’s most valuable properties is that fibrosis spontaneously regresses when the toxin is withdrawn. In wild-type mice that received CCl4 for eight weeks, hydroxyproline content dropped by about 43% over a 28-day recovery period. Markers of activated stellate cells fell back to control levels over the same window.⁵ Mice carrying a mutation that made their collagen resistant to breakdown, by contrast, showed no such recovery; their collagen stayed elevated and their stellate cells remained active. That experiment neatly demonstrated that collagen degradation by specific enzymes is essential for the liver to heal.

The speed of reversal also depends on how extensively the collagen has been cross-linked. An enzyme called lysyl oxidase (LOX) stabilizes collagen fibers by chemically locking them together, and higher LOX activity makes the scar tissue harder to dissolve. When researchers blocked LOX in fibrotic mice, fibrosis reversed faster after CCl4 was stopped.⁷ This finding has direct relevance for human disease, where advanced cirrhosis becomes increasingly irreversible partly because of collagen cross-linking.

Practical Details That Change Results

Running a CCl4 experiment sounds simple: dissolve the chemical in oil, inject mice, wait. In practice, the choice of oil vehicle, route of injection, dose, and schedule can dramatically change the outcome, and these details are a common source of variability between labs.

CCl4 is typically dissolved in a carrier oil and injected into the abdominal cavity (intraperitoneal injection) or delivered by mouth (oral gavage). These two routes do not produce identical effects. Intraperitoneal injection with a low ratio of oil to CCl4 triggers an early, intense spike of IL-6 in the abdominal cavity, a response that does not occur with oral dosing.⁸ This peritoneal inflammation is a confounding factor that has nothing to do with the liver itself, and it becomes more pronounced when less oil is used to dilute the CCl4.

The type of oil matters too. A head-to-head comparison of four common vehicles found that soybean oil and olive oil produced less liver damage and less fibrosis than corn oil or lard oil, even though the CCl4 dose was identical. The soybean oil group had significantly lower serum liver enzyme levels, less collagen accumulation, and less cell death.⁹ The likely explanation is that soybean and olive oils carry antioxidants that partially counteract the oxidative damage CCl4 causes. For researchers, this means the vehicle is not inert; it is part of the experiment. Standard protocols now specify the oil type to improve reproducibility.

Mouse Strain and Substrain Differences

Genetic background exerts a surprisingly large influence on CCl4-induced fibrosis. BALB/c mice develop severe fibrosis after CCl4 treatment, whereas C57BL/6 mice develop comparatively minimal fibrosis from the same protocol. The difference tracks with divergent immune responses: BALB/c mice mount a Th2-skewed cytokine profile that promotes scarring, while C57BL/6 mice lean toward a Th1 profile associated with less collagen deposition.¹⁰

Even substrains within C57BL/6 behave differently. The two most common substrains, C57BL/6J and C57BL/6N, diverged from each other decades ago and have accumulated distinct genetic differences. When both were given the same acute CCl4 dose, 6N mice showed more initial liver injury but repaired faster, partly because they recruited macrophages to the damaged area more quickly and regenerated hepatocytes sooner.¹¹ Because most genetically modified mice are built on one of these substrains, choosing the wrong background can confound a study entirely. A transgenic mouse on a 6J background may respond very differently from the same gene modification on a 6N background.

Sex-Dependent Responses

Female mice and rats consistently develop less severe fibrosis than males when exposed to the same CCl4 regimen, mirroring the clinical observation that chronic liver diseases such as fibrosis and cirrhosis are more common in men.¹² Two hormonal mechanisms are at work, and they push in the same direction.

Estrogen appears to be protective. In rats, estradiol treatment reduced serum markers of liver damage (ALT, AST), suppressed collagen content, and decreased the number of activated stellate cells in both sexes and in ovariectomized females.¹² More recent work in mice confirmed that estrogen deficiency worsened fibrotic injury in females, and supplementing estrogen in deficient females significantly reduced it.¹³

Testosterone, meanwhile, appears to aggravate damage. Male mice showed more severe acute injury and fibrosis than females, and castrating males reduced both. When castrated males were given testosterone supplements, liver inflammation and fibrosis worsened again, and this effect was linked to activation of the NLRP3 inflammasome, a key driver of the inflammatory response.¹⁴ Blocking the NLRP3 pathway with a specific inhibitor negated the testosterone-driven worsening, suggesting that androgens promote fibrosis through inflammation rather than through a direct effect on stellate cells.

These findings matter practically. Many older CCl4 studies used only male animals, which means their fibrosis timelines and dose-response curves may not apply to mixed-sex cohorts. Regulatory agencies now encourage the inclusion of both sexes in preclinical research, and the CCl4 model is one area where failing to do so could genuinely mislead conclusions about a drug’s anti-fibrotic potency.

How CCl4 Compares to Bile Duct Ligation

The other common method for inducing experimental liver fibrosis is bile duct ligation (BDL), a surgery in which the common bile duct is tied off so bile accumulates in the liver and causes damage. The two models produce fibrosis through different mechanisms and have different practical profiles.

BDL produces fibrosis faster, sometimes within two weeks, whereas CCl4 protocols typically require six to twelve weeks of repeated dosing to reach advanced fibrosis.¹⁵ But the nature of the fibrosis differs. CCl4 induces more steatosis (fat accumulation) and higher levels of TNF-α and leptin than BDL, reflecting the different injury pathways: metabolic and oxidative for CCl4, cholestatic (bile-driven) for BDL.¹⁶

BDL is considered safer for the researcher since it does not involve handling a volatile toxic chemical. CCl4 is a known carcinogen, and long-term exposure or inhalation during preparation carries a risk of liver tumors in the researcher, not just the animal.¹⁵ On the other hand, CCl4’s main advantage is versatility: the dose and schedule can be adjusted to produce anything from mild fibrosis to cirrhosis, and fibrosis reverses when dosing stops. BDL, being a surgical block, is essentially binary, and the fibrosis it causes is harder to reverse because the obstruction is permanent unless surgically relieved.

Non-invasive imaging techniques such as multiparametric MRI also behave differently in the two models, which matters for studies trying to validate imaging biomarkers. In rats, T2 mapping correlated well with fibrosis stage in BDL livers but performed poorly in CCl4 livers, while T1 mapping worked well in both.¹⁷ Researchers developing imaging tools for human liver disease need to be aware that an MRI sequence validated in one model may not transfer to the other.

Modeling Liver Cancer

CCl4 alone does not efficiently cause liver tumors in mice, but pairing it with a single early injection of diethylnitrosamine (DEN), a chemical carcinogen, creates one of the most reliable models of fibrosis-associated liver cancer. A single DEN injection followed by repeated CCl4 administration produces liver tumors in 100% of mice by five months of age.¹⁸ DEN initiates the cancer by causing DNA mutations, and CCl4 promotes it by maintaining the chronic inflammatory, fibrotic environment in which mutated cells thrive.

This two-hit protocol is valuable because most human hepatocellular carcinoma arises in fibrotic or cirrhotic livers. Models that skip the fibrosis step and jump straight to tumor formation miss the interplay between scarring and cancer that drives human disease. The DEN/CCl4 combination captures that interplay and has been used to study signaling pathways like Wnt/β-catenin in the context of tumor-promoting fibrosis.¹⁹

Testing Protective Compounds

The CCl4 model is a standard platform for screening compounds that might protect the liver or reverse fibrosis. Candidate drugs are typically given alongside or after CCl4, and their effects are measured by the same endpoints used to track fibrosis progression: serum ALT and AST levels, collagen content, stellate cell activation markers, and histological scores.

Silymarin (an extract from milk thistle) and taurine (an amino acid) are among the best-studied hepatoprotective agents in this model. In rats given CCl4, treatment with silymarin, taurine, or a combination of the two significantly reduced elevated liver enzymes, bilirubin, and hydroxyproline compared to untreated CCl4 animals. The combination outperformed either compound alone for some markers, suggesting synergy.²⁰ Amygdalin, a compound found in bitter almonds and apricot kernels, also reduced fibrosis markers in CCl4-treated rats, including collagen I, α-SMA, and liver enzyme levels.²¹

The model’s reproducibility is what makes it useful for drug screening, but it is worth keeping its limits in mind. A compound that counteracts free radical-driven injury (CCl4’s primary mechanism) might look like a powerful anti-fibrotic in this model while doing nothing for fibrosis caused by bile duct obstruction, viral infection, or metabolic dysfunction. Promising CCl4 results are a starting point, not proof that a drug will work in human liver disease.

The Gut-Liver Axis in CCl4-Induced Fibrosis

An area of growing interest is how CCl4 disrupts the gut. The liver receives most of its blood supply from the intestine, so gut barrier damage allows bacterial products like endotoxin to reach the liver and amplify inflammation. Recent work has shown that CCl4-induced fibrosis in mice is accompanied by intestinal barrier breakdown, including reduced expression of tight junction proteins that hold gut lining cells together, and shifts in the gut microbiome toward more pro-inflammatory bacterial species. A natural compound called deacetylasperulosidic acid methyl ester (DAM) not only reduced liver fibrosis markers in CCl4 mice but also restored intestinal barrier proteins and corrected the microbiome imbalance, reducing endotoxin translocation from the gut to the liver.²²

This gut-liver connection adds another layer to what the CCl4 model can teach us. It also means researchers need to account for housing conditions, diet, and even bedding type, all of which shape the gut microbiome and could influence how much fibrosis develops for a given CCl4 dose.

Tracking Fibrosis Without Killing the Animal

Traditionally, assessing fibrosis in CCl4-treated animals required sacrificing a group at each time point and examining their liver tissue under a microscope. This approach uses many animals and gives only snapshots. Non-invasive imaging is changing that. Multiparametric MRI, which combines several types of tissue contrast in a single scan, can now stage fibrosis in living mice with reasonable accuracy. In one study, native T1 mapping correlated well with fibrosis stage and produced an area under the curve of about 0.91 for distinguishing fibrotic from non-fibrotic liver. Combining multiple MRI measurements pushed accuracy higher still.¹⁷

What makes this particularly useful is that the same animal can be scanned repeatedly, allowing researchers to track fibrosis progression and regression in individual mice rather than relying on group averages. As these imaging tools are refined in preclinical models, they can be translated more directly to clinical MRI scanners for human patients, creating a tighter loop between the bench and the bedside.